SUBSCRIBERS
Takeda hikes outlook on cancer drug sales, Q3 profit jumps 60%
Published Thu, Feb 1, 2018 · 09:50 PM
Tokyo
TAKEDA Pharmaceutical Co Ltd said that its annual profit will outstrip a prior estimate and reach a six-year high, boosted by stronger sales of the cancer drug Velcade, after earlier reporting better-than-expected quarterly earnings.
Velcade is used to treat multiple myeloma, a type of blood cancer. A US court last year upheld Takeda's patent, giving the drug maker rights to exclusively sell the drug until 2022.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Nestle sales growth sputters on US slump, vitamin snags
Hermes Q1 sales jump 17% on strong China demand
Cordlife’s independent auditor to retire after issuing disclaimer of opinion on FY2023 financials
Cutting the cord?: Events leading up to Cordlife’s MOH suspension and arrests of its directors, ex-group CEO
Cordlife customers push for legal action
France's Casino supermarket chain to axe up to 3,200 jobs